iCAT for Recurrent/Refractory/HR Solid Tumors
Individualized Cancer Therapy (iCAT) Recommendation for Patients With Recurrent, Refractory or High Risk Solid Tumors
研究概览
详细说明
Some cancer-causing gene alterations (such as mutations or copy number alterations) are common or occur repeatedly in different types of cancers. For some of these alterations there are drugs, called targeted drugs that specifically counteract the alteration. In certain cancer types, these targeted drugs are very effective at fighting the cancer.
A tumor specimen that has been obtained previously or is planned to be obtained as part of clinical care will be used to perform tumor profiling. Additional procedures to obtain tumor will not be performed. An expert panel will review the results of the tumor profiling tests and determine whether a cancer-causing alteration is present and whether an individualized treatment recommendation can be made. If consent to sharing of the tumor profiling results and individualized treatment recommendation is provided then a study physician will discuss the profiling results and the individualized treatment recommendation with the primary oncologist. In addition, the primary oncologist will receive a letter detailing the tumor profiling results and the individualized treatment recommendation.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
California
-
San Francisco、California、美国、94143
- University of California, San Francisco
-
-
District of Columbia
-
Washington、District of Columbia、美国、20010
- Children's National Medical Center
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- Dana-Farber Cancer Institute
-
Boston、Massachusetts、美国、02215
- Boston Children's Hospital
-
-
New York
-
New York、New York、美国、10032
- Columbia University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Diagnosis of recurrent, refractory of high risk pediatric solid tumor (excluding brain tumor)
- Histologic proof of malignancy at the time of diagnosis or recurrence
- Sufficient tumor specimen available for profiling from diagnosis or recurrence, or surgery/biopsy planned for clinical care
Exclusion Criteria:
- Brain tumors
学习计划
研究是如何设计的？
设计细节
队列和干预
团体/队列 |
|---|
|
Refractory/Recurrent/High Risk Solid Tumors
|
研究衡量的是什么？
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Frequency of a cancer causing actionable alteration and individualized treatment recommendation.
大体时间：2 years
|
2 years
|
合作者和调查者
调查人员
- 首席研究员：Katherine Janeway, MD、Dana-Farber Cancer Institute
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.